Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $198,040.99 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 8,759 shares of Kestra Medical Technologies stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $22.61, for a total transaction of $198,040.99. Following the transaction, the insider directly owned 68,725 shares of the company’s stock, valued at approximately $1,553,872.25. This trade represents a 11.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

KMTS opened at $25.06 on Thursday. The firm has a fifty day moving average price of $22.78 and a 200 day moving average price of $22.52. Kestra Medical Technologies, Ltd. has a 1 year low of $14.10 and a 1 year high of $30.00. The stock has a market cap of $1.47 billion, a P/E ratio of -10.36 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million for the quarter. Equities research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on KMTS. Oppenheimer started coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research report on Wednesday, July 15th. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $27.83.

Institutional Trading of Kestra Medical Technologies

A number of institutional investors and hedge funds have recently modified their holdings of KMTS. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies during the 4th quarter worth about $31,000. Russell Investments Group Ltd. boosted its holdings in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after buying an additional 474 shares during the last quarter. Daiwa Securities Group Inc. purchased a new stake in Kestra Medical Technologies during the 4th quarter worth approximately $72,000. BNP Paribas Financial Markets increased its stake in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after buying an additional 1,638 shares in the last quarter. Finally, Brown Brothers Harriman & Co. raised its holdings in shares of Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.